Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeRestated

Transition to a Holding Company Structure Through a Sole-Share Transfer

First written in FY2022-Q1. 5 of 6 entries say "Restated". Latest entry: FY2024.

6entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY20242021: 220212022: 220222023: 120232024: 12024
Same theme, other companies
Transition to a Holding Company Structure through a Single-Company Share Transfer (4886)A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「Our group launched its holding company structure in FY2021 to enable agile decision-making and strengthen governance.」

    The holding company structure launched in FY2021 and its objectives of agile decision-making and stronger governance are reiterated.
  2. FY2023RestatedAnnual report

    「Our group launched its holding company structure in FY2021 to enable agile decision-making and strengthen governance.」

    The purpose of the holding company structure launched in FY2021 is reiterated.
  3. FY2022RestatedAnnual report

    「Our group launched its holding company structure in FY2021 to enable agile decision-making and strengthen governance.」

    The holding company structure launched in FY2021 is reiterated as a structure intended to enable agile decision-making and strengthen governance.
  4. FY2022-Q3RestatedAnnual report

    「As we were established on 1 April 2021 as the wholly owning parent company of Asuka Pharmaceutical Co., Ltd. through a sole-share transfer, comparisons with the previous fiscal year and the previous year’s corresponding quarter are not provided.」

    The holding company structure established on 1 April 2021 as the wholly owning parent company of Asuka Pharmaceutical Co., Ltd. through a sole-share transfer is reiterated.
  5. FY2022-Q2RestatedAnnual report

    「We were established on 1 April 2021 through a sole-share transfer as the wholly owning parent company of Asuka Pharmaceutical Co., Ltd.」

    The establishment of the holding company through a sole-share transfer is reiterated in the business description.
  6. FY2022-Q1First statedAnnual report

    「At a meeting of the board of directors of Asuka Pharmaceutical Co., Ltd. held on 23 March 2020 and the company’s 100th annual general meeting of shareholders held on 25 June 2020, resolutions were passed to establish ASKA Pharmaceutical Holdings Co.,Ltd. as a pure holding company and wholly owning parent company through a sole-share transfer. The company was established on 1 April 2021.」

    The group established a pure holding company on 1 April 2021 through a sole-share transfer.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.